Valneva SE (EPA:VLA)
France · Delayed Price · Currency is EUR | Market Cap | 430.50M +5.6% |
| Revenue (ttm) | 156.33M -16.0% |
| Net Income | -138.03M |
| EPS | -0.79 |
| Shares Out | 189.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 572,226 |
| Open | 2.165 |
| Previous Close | 2.179 |
| Day's Range | 2.152 - 2.278 |
| 52-Week Range | 2.135 - 5.415 |
| Beta | 1.41 |
| Analysts | Buy |
| Price Target | 5.23 (+130.4%) |
| Earnings Date | Aug 13, 2026 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2025, Valneva SE's revenue was 174.66 million, an increase of 3.00% compared to the previous year's 169.58 million. Losses were -115.19 million, 840.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VLA stock is "Buy." The 12-month stock price target is €5.23, which is an increase of 130.40% from the latest price.
News
Valneva Announces Successful Outcome of its Annual General Meeting
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that sh...
Valneva SE Registration statement: Registration filing
Valneva SE filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Valneva Announces Availability of Documentation for its Annual General Meeting
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meet...
Valneva SE Transcript: Jefferies Global Healthcare Conference 2026
The company highlighted strong progress in its Lyme vaccine program, with regulatory filings expected in autumn and potential launch in 2027. Key catalysts this year include the DoD contract for IXIARO and Shigella vaccine data. Significant commercial upside is anticipated, especially in Europe.
Valneva SE Slides: Investor presentation
Valneva SE has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Valneva to Participate at U.S. and European Investor Conferences in June
Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several...
Valneva SE Earnings Call Transcript: Q1 2026
Q1 2026 saw lower revenues and a widened net loss, driven by reduced travel vaccine demand and manufacturing costs. Major cost-cutting and restructuring are underway, with a revised sales outlook and continued R&D focus amid Lyme vaccine uncertainty.
Valneva SE Earnings release: Q1 2026
Valneva SE released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Valneva SE Slides: Q1 2026
Valneva SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Valneva SE Quarterly report: Q1 2026
Valneva SE has published its Q1 2026 quarterly earnings report on May 13, 2026.
Valneva Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ended March 31, 2026, provided key...
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
Lyon (France), May 05, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first quarter 2026 financial results on Wednesday, Ma...
Valneva Announces the Successful Completion of an €84 million Reserved Offering
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty...
Declaration of shares and voting rights of Valneva SE – March 2026
VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot S...
Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC
Lyon (France), March 26, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its participation in the upcoming 26th World Vaccine Congress, which will t...
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the resul...
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
Valneva SE Earnings Call Transcript: Q4 2025
2025 revenues slightly exceeded prior year, driven by proprietary vaccine growth and disciplined cash management, despite reduced third-party sales. Key pipeline programs advanced, with pivotal Lyme vaccine data expected H1 2026 and Shigella phase II data mid-year.
Valneva SE Earnings release: Q4 2025
Valneva SE released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Valneva SE Earnings release: Q4 2025
Valneva SE released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.